

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE FOURTH QUARTER ENDED 31 JULY 2024⁽¹⁾**

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	31.7.2024	31.7.2023	31.7.2024	31.7.2023
	RM'000	RM'000	RM'000	RM'000
Revenue	14,876	12,015	54,570	45,432
Cost of sales	(8,723)	(6,312)	(31,899)	(26,499)
Gross profit	6,153	5,703	22,671	18,933
Other income	383	506	1,561	1,895
Marketing expenses	(387)	(164)	(1,145)	(700)
Administrative and other expenses	(2,319)	(1,501)	(10,307)	(6,943)
Finance costs	(31)	(45)	(136)	(253)
Profit before tax	3,799	4,499	12,644	12,932
Taxation	(764)	(1,093)	(3,350)	(2,569)
Profit for the financial period/year	3,035	3,406	9,294	10,363
Other comprehensive income, net of tax	-	-	-	-
Total comprehensive income	3,035	3,406	9,294	10,363
Profit attributable to:				
Owners of the parent	3,035	3,370	8,987	10,315
Non-controlling interests	-	36	307	48
	3,035	3,406	9,294	10,363
Earnings per share attributable to owners of the parent ("EPS"):				
Basic and diluted ⁽²⁾ (sen)	0.81	0.90	2.40	2.76

Notes:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2023 and the accompanying explanatory notes attached to this interim financial report.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period/year under review.

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 JULY 2024⁽¹⁾

	Unaudited as at 31 July 2024 RM'000	Audited as at 31 July 2023 RM'000
ASSETS		
Non-current assets		
Property, plant and equipment	28,303	24,370
Right-of-use assets	4,689	4,810
Goodwill	287	287
Current assets		
Inventories	14,569	12,514
Trade and other receivables	20,089	12,799
Marketable securities	9,278	11,874
Current tax assets	1,219	525
Derivative assets	-	6
Cash and bank balances	4,232	6,107
TOTAL ASSETS	82,666	73,292
EQUITY AND LIABILITIES		
Equity		
Share capital	44,348	44,348
Reserves	27,633	18,646
Equity attributable to owners of the parent	71,981	62,994
Non-controlling interest	789	482
TOTAL EQUITY	72,770	63,476
Non-current liabilities		
Borrowings	256	2,877
Lease liabilities	-	7
Government grants	2,503	2,873
Deferred tax liabilities	1,154	307
Current liabilities		
Trade and other payables	4,463	2,583
Borrowings	606	711
Lease liabilities	14	44
Government grants	370	370
Current tax liabilities	530	44
TOTAL LIABILITIES	9,896	9,816
TOTAL EQUITY AND LIABILITIES	82,666	73,292

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 JULY 2024⁽¹⁾ (cont'd)

Note:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Financial Position is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2023 and the accompanying explanatory notes attached to this interim financial report.

UMediC Group Berhad
 (Company No. 202101015347) (1415647-D)
 (Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FOURTH QUARTER ENDED 31 JULY 2024⁽¹⁾

	Attributable to owners of the Parent						
	Non-distributable		Distributable		Total	Non-controlling interest	Total equity
	Share capital	Reorganisati on debit reserve	Retained earnings				
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	
Balance as at 1 August 2023	44,348	(6,851)	25,497	62,994	482	63,476	
Profit for the financial year	-	-	8,987	8,987	307	9,294	
Other comprehensive income, net of tax	-	-	-	-	-	-	
Total comprehensive income	-	-	8,987	8,987	307	9,294	
Balance as at 31 July 2024	44,348	(6,851)	34,484	71,981	789	72,770	

Note:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Changes in Equity is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2023 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE FOURTH QUARTER ENDED 31 JULY 2024⁽¹⁾

	12-month ended 31 July 2024 RM'000	12-month ended 31 July 2023 RM'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before tax	12,644	12,932
Adjustments for:		
Depreciation of property, plant and equipment	2,369	2,048
Depreciation of right-of-use assets	129	138
Amortisation of government grants	(370)	(370)
Finance costs	136	253
Gain on lease termination ⁽²⁾	-	*
Interest income	(202)	(108)
Distribution income from short-term fund	(373)	(303)
Property, plant and equipment written off	4	2
Realised gain on fair value adjustment on marketable securities	-	(268)
Reversal of impairment losses on trade receivables	26	(12)
Unrealised (gain)/loss on foreign exchange	(58)	142
Fair value adjustment on derivative asset	6	(6)
Operating profit before changes in working capital	14,311	14,448
Increase in inventories	(2,055)	(2,693)
Increase in trade and other receivables	(7,319)	(5,357)
Increase/(decrease) in trade and other payables	1,893	(2,450)
Cash generated from operations	6,830	3,948
Interest received	202	108
Tax paid	(2,890)	(2,677)
Tax refunded	179	424
Net cash from operating activities	4,321	1,803
CASH FLOWS FROM INVESTING ACTIVITIES		
Acquisition of subsidiary, net of cash acquired ⁽³⁾	-	287
Purchase of marketable securities	(5,150)	(25,800)
Purchase of property, plant and equipment	(6,306)	(5,313)
Proceeds from disposal of marketable securities	8,119	35,504
Net cash (used in)/from investing activities	(3,337)	4,678

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FOURTH QUARTER ENDED
31 JULY 2024⁽¹⁾ (Cont'd)**

	12-month ended 31 July 2024 RM'000	12-month ended 31 July 2023 RM'000
CASH FLOWS FROM FINANCING ACTIVITIES		
Capital contribution of non-controlling interest ⁽⁴⁾	*	300
Drawdown of bankers' acceptance	-	6,100
Repayment of bankers' acceptance	-	(7,550)
Repayment of term loans	(2,726)	(2,958)
Interest paid	(135)	(251)
Payment of lease liabilities	(46)	(55)
Net cash used in financing activities	(2,907)	(4,414)
Net (decrease)/increase in cash and cash equivalents	(1,923)	2,067
Effect of foreign exchange rates changes	48	(120)
Cash and cash equivalents at beginning of financial years	6,107	4,160
Cash and cash equivalents at end of financial years	4,232	6,107

Notes:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Cash Flows is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2023 and the accompanying explanatory notes attached to this interim financial report.
- (2) (1) There is a gain on lease terminations amounting to RM251 for financial year ended 31 July 2023.
- (3) The recognised amounts of assets acquired and liabilities assumed at the date of acquisition were:

	Pre-acquisition carrying amount RM'000
Property, plant and equipment	98
Right-of-use assets	59
Inventories	361
Trade and other receivables	93
Cash and cash equivalents	887
Deferred tax assets ^(a)	*
Lease liability	(60)
Trade and other payables	(981)
Current tax liabilities	(10)
Total identifiable net assets	447
	RM'000
Purchase consideration settled in cash and cash equivalents	600
Cash and cash equivalents	(887)
Net cash inflow on acquisition	(287)

Note:

- (a) There is deferred tax assets amounting to RM127.
- (4) There is capital contribution of non-controlling interest amounting to RM130 during the year.

A. NOTES TO THE INTERIM FINANCIAL REPORT

A1. Basis of preparation

The interim financial report of UMediC Group Berhad (“**UMC**” or the “**Company**”) and its subsidiaries (collectively, the “**Group**”) is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standard (“**MFRS**”) 134, Interim Financial Reporting issued by the Malaysian Accounting Standards Board (“**MASB**”) and Paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad (“Bursa Securities”) (“Listing Requirements”).

This interim financial report should be read in conjunction with the Group’s Audited Financial Statements for the financial year ended 31 July 2023 and the accompanying explanatory notes attached to this interim financial report.

A2. Significant Accounting Policies

The significant accounting policies and methods of computation applied in the unaudited condensed financial statements are consistent with those adopted in audited financial statements for the financial year ended 31 July 2023, except for the adoption of the following MFRSs and Amendment to MFRSs and Interpretation.

(a) New MFRSs adopted during the financial year

The Group and the Company adopted the following Amendments to the Standards of the MFRS Framework that were issued by the MASB during the financial periods:

Title	Effective Date
MFRS 17 <i>Insurance Contracts</i>	1 January 2023
Amendment to MFRS 17 <i>Insurance Contracts</i>	1 January 2023
Amendment to MFRS 17 <i>Initial Application of MFRS 17 and MFRS 9 - Comparative Information</i>	1 January 2023
Amendments to MFRS 101 <i>Disclosure of Accounting Policies</i>	1 January 2023
Amendments to MFRS 108 <i>Definition of Accounting Estimates</i>	1 January 2023
Amendments to MFRS 112 <i>Deferred Tax related to Assets and Liabilities arising from a Single Transaction</i>	1 January 2023
Amendments to MFRS 112 <i>International Tax Reform - Pillar Two Model Rules</i>	Refer paragraph 98M of MFRS112

Adoption of the above Amendments to the Standards did not have any material effect on the financial performance or position of the Group and of the Company.

(b) New MFRSs that have been issued, but only effective for annual periods beginning on or after 1 January 2024

The following are Standards of the MFRS Framework that have been issued by the MASB but have not been early adopted by the Group and the Company:

Title	Effective Date
Amendment to MFRS 16 <i>Lease Liability in a Sale and Leaseback</i>	1 January 2024
Amendments to MFRS 101 <i>Classification of Liabilities as Current or Non-current</i>	1 January 2024
Amendments to MFRS 101 <i>Non-current Liabilities with Covenants</i>	1 January 2024
Amendments to MFRS 107 <i>Statement of cash Flows</i> and MFRS 7 <i>Financial Instruments: Disclosure – Supplier Finance Arrangement</i>	1 January 2024
Amendments to MFRS 121 <i>Lack of Exchangeability</i>	1 January 2025
Amendments to MFRS 9 <i>Classification and Measurement of financial Instruments</i>	1 January 2026
Amendments to MFRS 18 <i>Presentation and Disclosure in Financial Statements</i>	1 January 2027
Amendments to MFRS 19 <i>Subsidiaries without Public Accountability: Disclosures</i>	1 January 2027
Amendments to MFRS 10 and MFRS 128 <i>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture</i>	Deferred

A2. Significant Accounting Policies (Cont'd)

The Group and the Company are in the process of assessing the impact of implementing these Amendments to Standards and Amendments to Standards, since the effects would only be observable for the future financial years.

A3. Auditors' Report

There was no qualification on the audited financial statements of the Group for the financial year ended 31 July 2023.

A4. Seasonal or Cyclical Factors

The business operations of the Group were not affected by any seasonal or cyclical trend during the current quarter and financial year under review.

A5. Material Unusual Items

There were no unusual items affecting the assets, liabilities, equity, net income or cash flows of the Group during the current quarter and financial year under review.

A6. Material Changes in Estimates

There were no changes in estimates that have a material effect in the current quarter and financial year under review.

A7. Debt and Equity Securities

There was no issuance, cancellation, repurchase, resale and repayment of debts and equity securities during the current quarter and financial year under review.

A8. Dividend Paid

No dividend was paid during the current quarter.

A9. Segmental Information

The Group is principally involved in investment holding. Through its subsidiaries, the Group is principally involved in marketing and distribution of various branded medical devices and consumables as well as the provision of after-sales service for all its products. The Group is also involved in developing, manufacturing and marketing of its medical consumables.

For management purposes, the Group is organised into business units based on its products and services. The reportable segments of the Group are as follows:

(a) Marketing and distribution – marketing and distribution of medical devices as well as the provision of after-sales service; and

(b) Manufacturing – developing, manufacturing and marketing of medical consumables.

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

A9. Segmental Information (Cont'd)

The Group's segmental information for the financial year under review is as follows:

31 July 2024	Manufacturing	Marketing and distribution	Eliminations	Consolidated
	RM'000	RM'000	RM'000	RM'000
Results				
Revenue from external customers	18,379	36,191	-	54,570
Inter-segment revenue	1,617	-	(1,617)	-
Total revenue	19,996	36,191	(1,617)	54,570
Interest income and distribution income from short-term fund	138	437	-	575
Interest expense	(23)	(121)	8	(136)
Net Interest income	115	316	8	439
Segment profit before tax	7,290	5,405	(51)	12,644

A10. Material Events Subsequent to the end of the Quarter

There were no other material events subsequent to the end of the current quarter and financial year under review that have not been reflected in this interim financial report.

A11. Changes in the Composition of the Group

On 20 May 2024, UMC had incorporated a 70% owned new subsidiary known as Akiteck (Malaysia) Sdn. Bhd. ("Akiteck") with paid-up share capital of RM100 comprising 100 ordinary shares. The intended principal activities of Akiteck are to design, assembly and distribution of medical moulting solution products and related parts.

On 30 July 2024, UMC had incorporated a 90% owned new subsidiary known as Ateria Medika Sdn. Bhd. ("Ateria Medika") with paid-up share capital of RM1,000 comprising 1,000 ordinary shares. The intended principal activities of Ateria Medika are to import, export, marketing and distribution of medical devices as well as the provision of after-sales service.

Apart from the above, there were no changes in the composition of the Group during the current quarter and financial year under review.

A12. Contingent Liabilities and Contingent Assets

There were no material contingent liabilities or contingent assets as at the date of this interim financial report.

A13. Material Capital Commitment

Save as disclosed below, as at 31 July 2024, the Group does not have any other material capital commitment:

	RM'000
Capital expenditure in respect of purchase of property, plant and equipment	
- Approved and contracted for	4,426
- Approved but not contracted for	6,843
Total	11,269

A14. Significant Related Party Transactions

There were no significant related party transactions during the current quarter.

UMediC Group Berhad
 (Company No. 202101015347) (1415647-D)
 (Incorporated in Malaysia under the Companies Act 2016)

A15. Derivative Financial Instruments

Derivatives

The Group has entered into forward foreign currency contracts with financial institutions due within 1 year to sell at contractual forward rates.

As at 31 July 2024, the Group's outstanding derivatives are as follow:

	Contract amount as at 31 July 2024		Fair value as at 31 July 2023
	USD'000	RM'000 equivalent	RM'000
Forward foreign currency contracts	-	-	810

A16. Fair Value of Financial Liabilities

The Group recorded a loss from fair value changes of the forward foreign currency contracts approximately RM5,625 during the financial year under review.

The fair value of a forward foreign currency contract is the amount that would be receivable upon termination of the outstanding position arising and is determined by reference to the difference between the contracted forward rate quoted by the financial institutions and the observable current market forward exchange rate as at the end of each reporting year.

The difference between the forward rates entered into, and the market rates, is recognised as derivatives asset or liability as applicable with a corresponding amount reported in the profit or loss.

(The remaining of this page is intentionally left blank)

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS

B1. Review of Performance

	Individual Quarter 3-months ended		Cumulative Quarter 12-months ended	
	31 July 2024 (RM'000)	31 July 2023 (RM'000)	31 July 2024 (RM'000)	31 July 2023 (RM'000)
Revenue	14,876	12,015	54,570	45,432
Profit before tax ("PBT")	3,799	4,499	12,644	12,932
Profit for the financial period/year	3,035	3,406	9,294	10,363
Profit attributable to owners of the parent	3,035	3,370	8,987	10,315

The Group's revenue increased by approximately RM2.86 million or 23.81% from approximately RM12.02 million achieved in the corresponding quarter of the previous financial year to approximately RM14.88 million in the current quarter.

The PBT of the Group decreased by approximately RM0.70 million or 15.56% from approximately RM4.50 million in the corresponding quarter of the previous financial year to approximately RM3.80 million in the current quarter.

The increase in revenue in the current quarter as compared to the corresponding quarter was contributed by both the marketing and distribution and manufacturing segments. The increase was mainly due to a higher demand for medical devices and consumables from both public and private hospitals as well as healthcare service providers. In addition, the increase in the Group's revenue was also contributed by the increase in the sale of its manufactured medical consumables, namely HydroX series prefilled humidifiers and AirdroX series inhaler spacers, with a better foreign exchange rate for the overseas revenue. However, the decrease in PBT was partially offset by an increase in administrative and other expenses, mainly attributable to increase in staff cost.

The Group's revenue increased by approximately RM9.14 million or 20.11% from approximately RM45.43 million achieved in the previous financial year to approximately RM54.57 million in the current financial year. However, the PBT of the Group decreased by approximately RM0.29 million or 2.23% from approximately RM12.93 million in the previous financial year to approximately RM12.64 million in the current financial year. The increase in revenue in the financial year was contributed by both the marketing and distribution and manufacturing segments. Despite the increase in the gross profit, the PBT decreased was mainly due to an increase in administrative and other expenses, mainly attributable to transfer listing expenses.

B2. Comparison with Immediate Preceding Quarter

	Individual Quarter 3-months ended			
	31 July 2024 (RM'000)	30 April 2024 (RM'000)	Differences	
			RM'000	%
Revenue	14,876	11,690	3,186	27.25
PBT	3,799	2,272	1,527	67.21
Profit for the financial period	3,035	1,596	1,439	90.16
Profit attributable to owners of the parent	3,035	1,583	1,452	91.72

The Group's revenue increased by approximately RM3.19 million or 27.25% from approximately RM11.69 million achieved in the immediate preceding quarter to approximately RM14.88 million in the current quarter. increase in revenue was mainly derived from the increase orders from marketing and distribution segment.

In view of the increase in revenue, the Group's PBT also increased by approximately RM1.53 million or 67.21% from approximately RM2.27 million achieved in the immediate preceding quarter to approximately RM3.80 million in the current quarter.

(The remaining of this page is intentionally left blank)

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

B3. Prospects

As the Malaysian government's unwavering commitment and ongoing pursuit to enhance the nation's healthcare standards, UMC embraces optimism towards its future ahead, anchored by several growth catalysts which stem from the growing demand for healthcare facilities upgrades, healthcare tourism as well as the crucial need to address overcrowding of facilities, fortifying the Group's pivotal role in the ever-evolving healthcare landscape.

The medical device industry in Malaysia is poised for growth and development, bolstered by a conducive environment for manufacturing and a mature healthcare system that is globally recognised. The Ministry of Health has received RM41.2 billion under Budget 2024, which is one of the biggest increases in terms of allocation. This 13.5% increase against the previous year's allocation of RM36.3 billion demonstrates the government's stance and resolute emphasis on improving the nation's quality of healthcare. This coincides with the Group's expectations of benefiting in the forthcoming financial periods.

To better bolster its presence within the medical industry, the Group has incorporated a new subsidiary known as Akiteck which was formed on 20 May 2024 with the intent to design, assemble and distribute medical moulting solution products and related parts. Subsequently, Ateria Medika was also formed with the intent to import, export, market and distribute medical devices as well as the provision of after-sales service. These incorporations are in line with the Group's strategic vision of expanding its portfolio and providing its end customers with a broader and more diversified selection of medical devices. By fostering the development of existing and new brands, the Group aims to meet the anticipated growing demand for both medical devices and further enhance its presence in the medical industry.

Barring unforeseen circumstances, the Group maintains confident of its growth trajectory.

B4. Profit Forecast

The Group did not issue any profit estimate, forecast, projection or internal targets in any public document.

B5. Taxation

The Group's taxation together with the comparison between the effective and statutory tax rates for the current quarter and financial period/year under review are as follows:

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	3-month ended 31 July 2024 RM'000	3-month ended 31 July 2023 RM'000	12-month ended 31 July 2024 RM'000	12-month ended 31 July 2023 RM'000
Income tax				
Current tax expenses based on profit for the financial period/year	663	643	2,456	1,870
Under/(over)provision of tax expense in prior years	-	10	47	(36)
Deferred tax				
Relating to origination and reversal of temporary differences	101	440	847	735
Under/(over)provision in prior years	-	(a)*	-	*
Overall tax expenses	764	1,093	3,350	2,569
Effective tax rate (%)	20.11	24.29	26.49	19.87
Statutory tax rate (%)	24.00	24.00	24.00	24.00

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

B5. Taxation (Cont'd)

Note:

* Represent less than RM1,000.

(a) There is an underprovision deferred tax in prior year amounting to RM616 during the current financial year.

The Group's effective tax rate was at 26.49% for current financial year. The effective tax rate for current financial year was higher than the statutory tax rate of 24.00% mainly due to the expenses not deductible for tax purposes in current year such as professional fees.

B6. Status of Corporate Proposals

There were no corporate proposals announced and not completed as at the date of this interim financial report.

B7. Utilisation of Proceeds from the IPO

The gross proceeds from the IPO amounting to RM31.11 million is expected to be utilised in the following manner:

Details of the use of proceeds	Estimated timeframe for the use of proceeds upon listing ⁽¹⁾	Proposed Utilisation RM'000	Actual Utilisation RM'000	Percentage utilised %	Deviation	
					RM'000	%
Capital expenditure						
(i) Construction of new factory building	Within thirty (30) months	3,500	3,334	95.26	-	-
(ii) Setting up new marketing and distribution offices	Within thirty-six (36) months	6,800	-	-	-	-
		10,300	3,334	32.37	-	-
Repayment of bank borrowings ⁽²⁾	Within six (6) months	9,000	9,000	100.00	-	-
Working capital	Within thirty-six (36) months	8,662	8,662	100.00	-	-
Estimated listing expenses	Within two (2) months	3,150	3,150	100.00	-	-
Total		31,112	24,146			

Notes:

- (1) From the date of listing of the Company on the ACE Market of Bursa Securities on 26 July 2022.
- (2) Including lease liabilities owing to financial institutions.

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

B8. Group Borrowings and Debt Securities

The details of the Group's borrowings are as follows:

	12-month ended 31 July 2024 RM'000	Audited as at 31 July 2023 RM'000
Current liabilities		
Term loan	606	711
	606	711
Non-current liabilities		
Term loan	256	2,877
	256	2,877
Total borrowings	862	3,588

All the Group's borrowings are denominated in RM, secured and interest-bearing.

B9. Material Litigation

As at the date of this interim financial report, the Group is not engaged in any material litigation or arbitration proceedings, either as plaintiff or defendant, and the Directors are not aware of any proceedings pending or threatened against the Group, which may materially and adversely affect the financial position or business performance of the Group.

B10. Dividend

No dividend has been declared or recommended for the current quarter ended 31 July 2024.

B11. Earnings Per Share

The basic and diluted EPS for the current quarter and financial period/year are computed as follows:

	3-month ended 31 July 2024	3-month ended 31 July 2023	12-month ended 31 July 2024	12-month ended 31 July 2023
Profit attributable to the owners of the parent (RM'000)	3,035	3,370	8,987	10,315
Number of ordinary shares (unit) ('000)	373,910	373,910	373,910	373,910
Basic EPS ⁽¹⁾ (sen)	0.81	0.90	2.40	2.76
Diluted EPS ⁽²⁾ (sen)	0.81	0.90	2.40	2.76

Notes:

- (1) Basic EPS is calculated by dividing the profit attributable to owners of the parent by the number of ordinary shares outstanding during the financial period/year under review.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period/year under review.

(The remaining of this page is intentionally left blank)

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

B.12 Profit Before Tax

Profit before tax is arrived at after charging/(crediting):

	12-month ended 31 July 2024	12-month ended 31 July 2023
	RM'000	RM'000
Depreciation of property, plant and equipment	2,369	2,048
Depreciation of right-of-use assets	129	138
Amortisation of government grants	(370)	(370)
Finance costs	136	253
Gain on lease terminations ⁽¹⁾	-	*
Interest income	(202)	(108)
Distribution income from short-term fund	(373)	(303)
Property, plant and equipment written off	4	2
Realised gain on fair value adjustment on marketable securities	-	(268)
Reversal of impairment losses on trade receivables	26	(12)
Unrealised (gain)/loss on foreign exchange	(58)	142
Fair value loss on derivative asset	6	(6)

Notes:

* Represent less than RM1,000.

(1) There is a gain on lease terminations amounting to RM250 for financial year ended 31 July 2023.

Save as disclosed above, the other disclosure items pursuant to Note 16, of Appendix 9B of the Listing Requirements are not applicable.

BY ORDER OF THE BOARD
4 September 2024